Reproducibility and variability of activated clotting time measurements in the cardiac catheterization laboratory

被引:38
作者
Doherty, TM
Shavelle, RM
French, WJ
机构
[1] Univ Calif Los Angeles, Los Angeles Cty Harbor Med Ctr, Dept Med, Div Cardiol, Torrance, CA 90509 USA
[2] Life Expectancy Project, San Francisco, CA USA
关键词
anticoagulation; whole blood activated coagulation time; prothrombin time; activated partial thromboplastin time; heparin;
D O I
10.1002/ccd.20355
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The objective of this study was to characterize the reproducibility and variability in the measurement to the activated clotting time (ACT) when performed on two different types of instruments, the HemoTec ACT (Medtronic) and the Hemochron 801 (international Technidyne). The ACT has evolved into the most common point-of-care test used in the cardiac catheterization lab to manage patient heparinization. Since the test has not been standardized, different systems frequently produce different results under the same clinical conditions. Duplicate paired ACT tests (n = 885) from 359 patients were performed on both instruments. Prothrombin times (PT) and activated partial thromboplastin times (aPTT) were also determined on subsets of these same samples (PT = 533; aPTT = 487). The performance and relationships between the two tests were determined using a variety of statistical analytical techniques. The average difference between the ACT devices was only 8 sec, yet more than 60% of the measurements varied by more than 10%. Over one-fourth of measurements varied by more than 20%. The reproducibility to the HemoTec instrument was superior to the Hemochron instrument across the entire range of ACTs measured (mean coefficient of variation 2.4% +/- 3.1% vs. 7.2% +/- 6.1% for HemoTec and Hemochron, respectively; P < 0.00001; range 65-555 sec). The relationship between the two ACTs was nonlinear. In therapeutic ranges used for interventional procedures (200-350 sec), HemoTec and Hemochron ACTs are not comparable to one another. Statistical comparative analysis indicated that the HemoTec ACT has better overall performance. (c) 2005 Wiley-Liss, Inc.
引用
收藏
页码:330 / 337
页数:8
相关论文
共 36 条
[1]   BLEEDING COMPLICATIONS WITH THE CHIMERIC ANTIBODY TO PLATELET GLYCOPROTEIN IIB/IIIA INTEGRIN IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION [J].
AGUIRRE, FV ;
TOPOL, EJ ;
FERGUSON, JJ ;
ANDERSON, K ;
BLANKENSHIP, JC ;
HEUSER, RR ;
SIGMON, K ;
TAYLOR, M ;
GOTTLIEB, R ;
HANOVICH, G ;
ROSENBERG, M ;
DONOHUE, TJ ;
WEISMAN, HF ;
CALIFF, RM .
CIRCULATION, 1995, 91 (12) :2882-2890
[2]   MEASUREMENT IN MEDICINE - THE ANALYSIS OF METHOD COMPARISON STUDIES [J].
ALTMAN, DG ;
BLAND, JM .
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES D-THE STATISTICIAN, 1983, 32 (03) :307-317
[3]   In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time [J].
Ammar, T ;
Scudder, LE ;
Coller, BS .
CIRCULATION, 1997, 95 (03) :614-617
[4]   COMPARISON OF HEMOCHRON AND HEMOTEC ACTIVATED COAGULATION TIME TARGET VALUES DURING PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY [J].
AVENDANO, A ;
FERGUSON, JJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1994, 23 (04) :907-910
[5]   New technology, old standards: Disparate activated clotting time measurements by the Hemochron Jr compared with the standard hemochron [J].
Aylsworth, CL ;
Stefan, F ;
Woitas, K ;
Rieger, RH ;
LeBoutillier, M ;
DiSesa, VJ .
ANNALS OF THORACIC SURGERY, 2004, 77 (03) :973-976
[6]   Relation between abrupt vessel closure and the anticoagulant response to heparin or bivalirudin during coronary angioplasty [J].
Bittl, JA ;
Ahmed, WH .
AMERICAN JOURNAL OF CARDIOLOGY, 1998, 82 (8B) :50P-56P
[7]   STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT [J].
BLAND, JM ;
ALTMAN, DG .
LANCET, 1986, 1 (8476) :307-310
[8]   Vascular access site complications after percutaneous coronary intervention with abciximab in the evaluation of c7E3 for the prevention of ischemic complications (EPIC) trial [J].
Blankenship, JC ;
Hellkamp, AS ;
Aguirre, FV ;
Demko, SL ;
Topol, EJ ;
Califf, RM .
AMERICAN JOURNAL OF CARDIOLOGY, 1998, 81 (01) :36-40
[9]  
BOOKBINDER MJ, 1987, CLIN CHEM, V33, P1170
[10]   Revisiting optimal anticoagulation with unfractionated heparin during coronary stent implantation [J].
Brener, SJ ;
Bhatt, DL ;
Moliterno, DJ ;
Schneider, JP ;
Ellis, SG ;
Topol, EJ .
AMERICAN JOURNAL OF CARDIOLOGY, 2003, 92 (12) :1468-1471